Nektar Therapeutics (NKTR) is a publicly traded Healthcare sector company. As of May 21, 2026, NKTR trades at $69.51 with a market cap of $2.31B and a P/E ratio of -8.33. NKTR moved +2.89% today. Year to date, NKTR is +56.26%; over the trailing twelve months it is +574.24%. Its 52-week range spans $6.48 to $109.00. Analyst consensus is strong buy with an average price target of $153.71. Rallies surfaces NKTR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in NKTR news today?
Nektar Therapeutics closes $373.8 M offering, reports $44.9 M Q1 net loss, advances Phase 3: Nektar reported Q1 2026 revenue of $10.9 million, operating expenses of $49.9 million and net loss of $44.9 million ($1.82/share), supported by $731.6 million in cash and marketable securities as of March 31, 2026 (excluding $351 million raised in April). The company raised $373.8 million in an April public offering, will initiate its Phase 3 ZENITH-AD program in atopic dermatitis by July and expects an End-of-Phase 2 FDA meeting for alopecia areata this quarter.
Nektar Therapeutics closes $373.8 M offering, reports $44.9 M Q1 net loss, advances Phase 3: Nektar reported Q1 2026 revenue of $10.9 million, operating expenses of $49.9 million and net loss of $44.9 million ($1.82/share), supported by $731.6 million in cash and marketable securities as of March 31, 2026 (excluding $351 million raised in April). The company raised $373.8 million in an April public offering, will initiate its Phase 3 ZENITH-AD program in atopic dermatitis by July and expects an End-of-Phase 2 FDA meeting for alopecia areata this quarter.
Does Rallies summarize NKTR news?
Yes. Rallies summarizes NKTR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is NKTR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NKTR. It does not provide personalized investment advice.
